1 of 2 ATTY DOCKET NO. APPLICATION NO. Form PTO-1449 US Dept. of Commerce (REV. 1/06) PATENT & TRADEMARK OFFICE 128125 10/582,674 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) APPLICANT(S) Herve PERRON et al. FILING DATE June 12, 2006 U.S. PATENT DOCUMENTS Examiner Cite Initials No. Document Number Date Name /D.K./ 07/25/2006 7,081,345 B1 Roecklin et al. FOREIGN PATENT DOCUMENTS Examiner Cite With With Initials Document Number Date Country English English No. Abstract Translation OTHER DOCUMENTS Examiner Cite (Including Author, Title, Date, Pertinent Pages, etc.) Initials No. Rieger, F. et al., "Un facteur gliotoxique et la sclérose en plaques - Gliotoxicity in multiple sclerosis," C. R. Acad. Paris, Sciences de la vie/Life sciences 319: 343-350 (1996) /D.K./ Malcus-Vocanson, C. et al., "Glial toxicity in urine and multiple sclerosis," Multiple Sclerosis 7: 383-388 (2001) /D.K./ 4. Ménard, A. et al., "A gliotoxic factor and multiple sclerosis," Journal of Neurological Sciences 154: 209-221 (1998) /D.K./ Malcus-Vocanson, C. et al., "A urinary marker for multiple sclerosis," Lancet 351: 1330 (May 1998) /D.K./ Ménard, A. et al., "Gliotoxicity, reverse transcriptase activity and retroviral RNA in monocyte/macrophage culture supernatants 6. /D.K./ from patients with multiple sclerosis," FEBS Letters 413: 477-485 (1997) 7. Ménard, A. et al., "Detection of a gliotoxic activity in the cerebrospinal fluid from multiple sclerosis patients," Neuroscience Letters 245: 49-52 (1998) /D.K./ 8. Benjelloun, N. et al., "DNA Fragmentation in Glial Cells in a Cerebral Biopsy from a Multiple Sclerosis Patient," Cellular and Molecular Biology 44(4): 579-583 (1998) /D.K./ 9 Blazar, B.R. et al., "Anti-CD3EF(ab")2 Fragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen," Journal of Immunology 159: 5821-5833 (1997) /D.K./ 10. Bird, R.E. et al., "Single-Chain Antigen-Binding Proteins," Science 242: 423-426 (October 1988) /D.K./ **EXAMINER** DATE CONSIDERED Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: September 1, 2006

Sheet 2 of 2 APPLICATION NO. ATTY DOCKET NO. Form PTO-1449 US Dept. of Commerce (REV. 1/06) PATENT & TRADEMARK OFFICE 128125 10/582,674 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) APPLICANT(S) Herve PERRON et al. **GROUP** FILING DATE June 12, 2006 U.S. PATENT DOCUMENTS Cite Examiner Initials No. Document Number Date Name FOREIGN PATENT DOCUMENTS Examiner Cite With With English Initials Document Number Date Country English No. Abstract Translation OTHER DOCUMENTS Examiner Cite (Including Author, Title, Date, Pertinent Pages, etc.) Initials No. 11. Arakawa, F. et al., "Cloning and Sequencing of the VH and VK Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," Journal of Biochemistry 120: 657-662 (1996) /D.K./ 12. Chaudhary, V.K. et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas extotoxin," Nature 339: 394-397 (June 1989) /D.K./ 13. Jones, P.T. et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature 321: 522-525 (May 1986) /D.K./ 14. Riechmann, L. et al., "Reshaping human antibodies for therapy," Nature 332: 323-327 (March, 1988) /D.K./ 15. Galiana, E. et al., "Establishment of Permanent Astroglial Cell Lines, Able to Differentiate in Vitro, From Transgenic Mice Carrying the Polyoma Virus Large T Gene: An Alternative Approach to Brain Cell Immortalization," Journal of Neuroscinece /D.K./ Research 26: 269-277 (1990) **EXAMINER** DATE CONSIDERED /Daniel Kolker/ 09/03/2008 Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: September 1, 2006